These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29721042)

  • 1. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
    Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
    J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy.
    Morgans AK; Grewal S; Hepp Z; Fuldeore R; Odak S; Macahilig C; Shillington AC; Sonpavde G
    Clin Genitourin Cancer; 2022 Dec; 20(6):543-552. PubMed ID: 36088235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
    Bilen MA; Robinson SB; Schroeder A; Peng J; Kim R; Liu FX; Bhanegaonkar A
    Oncologist; 2023 Sep; 28(9):790-798. PubMed ID: 37432283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.
    Galsky MD; Pal SK; Lin SW; Ogale S; Zivkovic M; Simpson J; Derleth C; Schiff C; Sonpavde G
    Bladder Cancer; 2018 Apr; 4(2):227-238. PubMed ID: 29732393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
    Auclin E; Benitez-Montanez J; Tagliamento M; Parisi F; Gorria T; Garcia-Campelo R; Dempsey N; Pinato DJ; Reyes R; Albarrán-Artahona V; Dall'Olio F; Soldato D; Hendriks L; Nana FA; Tonneau M; Lopez-Castro R; Nadal E; Kazandjian S; Muanza T; Blanc-Durand F; Fabre E; Castro N; Arasanz H; Rochand A; Besse B; Routy B; Mezquita L
    Lung Cancer; 2023 Apr; 178():116-122. PubMed ID: 36812760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States.
    Geynisman DM; Broughton E; Hao Y; Zhang Y; Le T; Huo S
    Urol Oncol; 2022 May; 40(5):195.e1-195.e11. PubMed ID: 34906410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
    Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
    Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States.
    Moon HH; Kearney M; Mahmoudpour SH; Ike C; Morris V; Rava A; Kim S; Sun H; Boyd M; Gomez Rey G
    Curr Oncol; 2024 Sep; 31(9):5662-5676. PubMed ID: 39330048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Analysis of Treatment Patterns and Platinum-Based Treatment Eligibility of Patients With Metastatic Urothelial Cancer in 5 European Countries.
    Milloy N; Kirker M; Unsworth M; Montgomery R; Kluth C; Kearney M; Chang J
    Clin Genitourin Cancer; 2024 Feb; 22(1):e136-e147.e1. PubMed ID: 37945404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
    Hepp Z; Shah SN; Smoyer K; Vadagam P
    J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results.
    Nathan P; Venugopal B; Ali J; Allison J; Ceruso M; Charnley N; Griffiths R; Michael A; Moore K; Perrot V; Prendergast Á; Sharma A; Szabados B; Larkin J
    Clin Genitourin Cancer; 2024 Oct; 22(5):102141. PubMed ID: 39107157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Aguin S; Carral A; Iglesias L; Pena C; Molina A; Costa M; Covela M; Gomez JG; Arroyo RG; Huidobro G; Simo RV; Medina A
    Cancer Diagn Progn; 2023; 3(2):264-271. PubMed ID: 36875311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.
    Grivas P; Grande E; Davis ID; Moon HH; Grimm MO; Gupta S; Barthélémy P; Thibault C; Guenther S; Hanson S; Sternberg CN
    ESMO Open; 2023 Dec; 8(6):102050. PubMed ID: 37976999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
    Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A; Bilen MA; Stewart T; Santos V; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
    Eur Urol Oncol; 2021 Jun; 4(3):464-472. PubMed ID: 33423945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Navani V; Wells JC; Boyne DJ; Cheung WY; Brenner DM; McGregor BA; Labaki C; Schmidt AL; McKay RR; Meza L; Pal SK; Donskov F; Beuselinck B; Otiato M; Ludwig L; Powles T; Szabados BE; Choueiri TK; Heng DYC
    Clin Genitourin Cancer; 2023 Feb; 21(1):106.e1-106.e8. PubMed ID: 35945133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study.
    Blackhall F; Girard N; Livartowski A; McDonald L; Roset M; Lara N; Juarez García A
    BMJ Open; 2023 Feb; 13(2):e052556. PubMed ID: 36746549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
    Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR
    Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
    Alholm Z; Monk BJ; Ting J; Pulgar S; Boyd M; Sudharshan L; Bains S; Nicacio L; Coleman RL
    Gynecol Oncol; 2021 May; 161(2):422-428. PubMed ID: 33741208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain.
    Badiola LB; Milagro NL; Lavín DC; Peraita SL; Ibarbia MA; Kareaga MM; Fernández Del Rivero TP; Otero DSP; López VA; Fernández CÁ; Emborujo AL; Arnaiz IG; Rodríguez RF; Verdún-Aguilar J; Sagastibeltza N; Duran I;
    Semin Oncol; 2024; 51(3-4):77-86. PubMed ID: 38604897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.
    Morgans AK; Galsky MD; Wright P; Hepp Z; Chang N; Willmon CL; Sesterhenn S; Liu Y; Sonpavde GP
    Urol Oncol; 2023 Aug; 41(8):357.e11-357.e21. PubMed ID: 37208230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.